Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
With a market cap of 13.4B, Moderna(MRNA) trades at $34.35. The stock has a price-to-earnings ratio of -4.25.
On 2026-01-11, Moderna(MRNA) stock traded between a low of $33.94 and a high of $35.41. Shares are currently priced at $34.35, which is +1.2% above the low and -3.0% below the high.
Moderna(MRNA) shares are trading with a volume of 7.55M, against a daily average of 9.78M.
In the last year, Moderna(MRNA) shares hit a 52-week high of $45.40 and a 52-week low of $22.28.
In the last year, Moderna(MRNA) shares hit a 52-week high of $45.40 and a 52-week low of $22.28.
MRNA News
In early January 2026, Moderna reported positive Phase 3 data and submitted regulatory applications in the U.S., EU, Canada, and Australia for its mRNA-1010 sea...
Investors in Moderna Inc (Symbol: MRNA) saw new options begin trading today, for the February 27th expiration. At Stock Options Channel , our YieldBoost formula...
Mixed options sentiment in Moderna (MRNA), with shares up 28c, or 0.79%, near $35.94. Options volume running well above average with 52k contracts traded and ca...
Analyst ratings
65%
of 26 ratingsMore MRNA News
Within the first week of 2026, the S&P 500 leaderboard has already delivered a surprise. Moderna Inc (NASDAQ:MRNA) has quietly muscled its way into the top year...
These companies are leaders in their fields. At the start of a new year, we all like to make positive moves that may serve us well in the coming months and ove...
Moderna MRNA shares soared 10.9% in the last trading session to close at $35.66. The move was backed by solid volume with far more shares changing hands than in...
UBS analysts downgraded Moderna (MRNA) stock to Hold from Buy and cut its price target to $34 from $40. The firm warned that the biotechnology company’s nearly...
Moderna rallies after BofA raises its price target to $24 from $21 Moderna rose on Tuesday after Bank of America analysts raised their price target for the ail...
Moderna (MRNA) provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 years and older. T...